Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach

  • Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel (Korean Gastric Cancer Association (KGCA))
  • Received : 2018.12.17
  • Accepted : 2019.02.14
  • Published : 2019.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Jung KW, Won YJ, Kong HJ, Lee ES; Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat 2018;50:303-316. https://doi.org/10.4143/crt.2018.143
  2. Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer 2014;14:87-104. https://doi.org/10.5230/jgc.2014.14.2.87
  3. The Korean Gastric Cancer Association.Korean guideline for gastric cancer. J Korean Gastric Cancer Assoc2004;4:286-293. https://doi.org/10.5230/jkgca.2004.4.4.286
  4. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. https://doi.org/10.1136/bmj.d5928
  5. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013;66:408-414. https://doi.org/10.1016/j.jclinepi.2012.09.016
  6. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009;62:1013-1020. https://doi.org/10.1016/j.jclinepi.2008.10.009
  7. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-536. https://doi.org/10.7326/0003-4819-155-8-201110180-00009
  8. Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developer's handbook [Internet]. Edinburgh: Scottish Intercollegiate Guidelines Network; 2015 [cited 2018 Sep 23]. Available from: http:// www.sign.ac.uk.
  9. Schunemann H, Brozek J, Guyatt G, Oxman A, eds. GRADE Handbook: Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach. [place unknown]: The GRADE Working Group, 2013.
  10. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, eds. AJCC Cancer Staging Manual. 8th ed. New York (NY): Springer International Publishing, 2017.
  11. Chung IK, Lee JH, Lee SH, Kim SJ, Cho JY, Cho WY, et al. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD study group multicenter study. Gastrointest Endosc 2009;69:1228-1235. https://doi.org/10.1016/j.gie.2008.09.027
  12. Kim SG, Lyu DH, Park CM, Lee NR, Kim J, Cha Y, et al. Current status of endoscopic submucosal dissection for early gastric cancer in Korea: role and benefits. Korean J Intern Med 2018. doi: 10.3904/ kjim.2017.374 [In press].
  13. Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000;3:219-225. https://doi.org/10.1007/PL00011720
  14. Nishizawa T, Yahagi N. Long-term outcomes of using endoscopic submucosal dissection to treat early gastric cancer. Gut Liver 2018;12:119-124. https://doi.org/10.5009/gnl17095
  15. Kim SG, Park CM, Lee NR, Kim J, Lyu DH, Park SH, et al. Long-term clinical outcomes of endoscopic submucosal dissection in patients with early gastric cancer: a prospective multicenter cohort study. Gut Liver 2018;12:402-410. https://doi.org/10.5009/gnl17414
  16. Choi IJ, Lee JH, Kim YI, Kim CG, Cho SJ, Lee JY, et al. Long-term outcome comparison of endoscopic resection and surgery in early gastric cancer meeting the absolute indication for endoscopic resection. Gastrointest Endosc 2015;81:333-341.e1. https://doi.org/10.1016/j.gie.2014.07.047
  17. Choi KS, Jung HY, Choi KD, Lee GH, Song HJ, Kim DH, et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. Gastrointest Endosc 2011;73:942-948. https://doi.org/10.1016/j.gie.2010.12.032
  18. Hahn KY, Park CH, Lee YK, Chung H, Park JC, Shin SK, et al. Comparative study between endoscopic submucosal dissection and surgery in patients with early gastric cancer. Surg Endosc 2018;32:73-86. https://doi.org/10.1007/s00464-017-5640-8
  19. Song M, Choi JY, Yang JJ, Sung H, Lee Y, Lee HW, et al. Obesity at adolescence and gastric cancer risk. Cancer Causes Control 2015;26:247-256. https://doi.org/10.1007/s10552-014-0506-z
  20. Kim YI, Kim YA, Kim CG, Ryu KW, Kim YW, Sim JA, et al. Serial intermediate-term quality of life comparison after endoscopic submucosal dissection versus surgery in early gastric cancer patients. Surg Endosc 2018;32:2114-2122. https://doi.org/10.1007/s00464-017-5909-y
  21. Honda M, Hiki N, Kinoshita T, Yabusaki H, Abe T, Nunobe S, et al. Long-term outcomes of laparoscopic versus open surgery for clinical stage I gastric cancer: the LOC-1 study. Ann Surg 2016;264:214-222. https://doi.org/10.1097/SLA.0000000000001654
  22. Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol 2014;32:627-633.
  23. Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg 2016;263:28-35. https://doi.org/10.1097/SLA.0000000000001346
  24. Lee S, Choi KD, Hong SM, Park SH, Gong EJ, Na HK, et al. Pattern of extragastric recurrence and the role of abdominal computed tomography in surveillance after endoscopic resection of early gastric cancer: Korean experiences. Gastric Cancer 2017;20:843-852. https://doi.org/10.1007/s10120-017-0691-z
  25. Min BH, Kim ER, Kim KM, Park CK, Lee JH, Rhee PL, et al. Surveillance strategy based on the incidence and patterns of recurrence after curative endoscopic submucosal dissection for early gastric cancer. Endoscopy 2015;47:784-793. https://doi.org/10.1055/s-0034-1392249
  26. Oda I, Oyama T, Abe S, Ohnita K, Kosaka T, Hirasawa K, et al. Preliminary results of multicenter questionnaire study on long-term outcomes of curative endoscopic submucosal dissection for early gastric cancer. Dig Endosc 2014;26:214-219. https://doi.org/10.1111/den.12141
  27. Kim TS, Min BH, Kim KM, Lee JH, Rhee PL, Kim JJ. Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: low curative resection rate but favorable long-term outcomes after curative resection. Gastric Cancer 2019;22:363-368. https://doi.org/10.1007/s10120-018-0857-3
  28. Chang JY, Shim KN, Tae CH, Lee KE, Lee J, Lee KH, et al. Comparison of clinical outcomes after endoscopic submucosal dissection and surgery in the treatment of early gastric cancer: a single-institute study. Medicine (Baltimore) 2017;96:e7210. https://doi.org/10.1097/MD.0000000000007210
  29. Chiu PW, Teoh AY, To KF, Wong SK, Liu SY, Lam CC, et al. Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study. Surg Endosc 2012;26:3584-3591. https://doi.org/10.1007/s00464-012-2371-8
  30. Cho JH, Cha SW, Kim HG, Lee TH, Cho JY, Ko WJ, et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a comparison study to surgery using propensity score-matched analysis. Surg Endosc 2016;30:3762-3773. https://doi.org/10.1007/s00464-015-4672-1
  31. Feng F, Sun L, Xu G, Cai L, Hong L, Yang J, et al. Is it reasonable to treat early gastric cancer with mucosal infiltration and well differentiation by endoscopic submucosal resection? J Gastrointest Surg 2015;19:2111-2119. https://doi.org/10.1007/s11605-015-2932-y
  32. Fukunaga S, Nagami Y, Shiba M, Ominami M, Tanigawa T, Yamagami H, et al. Long-term prognosis of expanded-indication differentiated-type early gastric cancer treated with endoscopic submucosal dissection or surgery using propensity score analysis. Gastrointest Endosc 2017;85:143-152. https://doi.org/10.1016/j.gie.2016.06.049
  33. Gong EJ, Kim DH, Ahn JY, Jung KW, Lee JH, Choi KD, et al. Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma. Gastric Cancer 2017;20:84-91. https://doi.org/10.1007/s10120-016-0679-0
  34. Kim YI, Kim YW, Choi IJ, Kim CG, Lee JY, Cho SJ, et al. Long-term survival after endoscopic resection versus surgery in early gastric cancers. Endoscopy 2015;47:293-301. https://doi.org/10.1055/s-0034-1391284
  35. Lee S, Choi KD, Han M, Na HK, Ahn JY, Jung KW, et al. Long-term outcomes of endoscopic submucosal dissection versus surgery in early gastric cancer meeting expanded indication including undifferentiatedtype tumors: a criteria-based analysis. Gastric Cancer 2018;21:490-499. https://doi.org/10.1007/s10120-017-0772-z
  36. Park CH, Lee H, Kim DW, Chung H, Park JC, Shin SK, et al. Clinical safety of endoscopic submucosal dissection compared with surgery in elderly patients with early gastric cancer: a propensity-matched analysis. Gastrointest Endosc 2014;80:599-609. https://doi.org/10.1016/j.gie.2014.04.042
  37. Pyo JH, Lee H, Min BH, Lee JH, Choi MG, Lee JH, et al. Long-term outcome of endoscopic resection vs. surgery for early gastric cancer: a non-inferiority-matched cohort study. Am J Gastroenterol 2016;111:240-249. https://doi.org/10.1038/ajg.2015.427
  38. Shin DW, Hwang HY, Jeon SW. Comparison of endoscopic submucosal dissection and surgery for differentiated type early gastric cancer within the expanded criteria. Clin Endosc 2017;50:170-178. https://doi.org/10.5946/ce.2016.017
  39. Eom BW, Kim YI, Kim KH, Yoon HM, Cho SJ, Lee JY, et al. Survival benefit of additional surgery after noncurative endoscopic resection in patients with early gastric cancer. Gastrointest Endosc 2017;85:155-163.e3. https://doi.org/10.1016/j.gie.2016.07.036
  40. Hatta W, Gotoda T, Oyama T, Kawata N, Takahashi A, Yoshifuku Y, et al. Is radical surgery necessary in all patients who do not meet the curative criteria for endoscopic submucosal dissection in early gastric cancer? A multi-center retrospective study in Japan. J Gastroenterol 2017;52:175-184. https://doi.org/10.1007/s00535-016-1210-4
  41. Kim ER, Lee H, Min BH, Lee JH, Rhee PL, Kim JJ, et al. Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer. Br J Surg 2015;102:1394-1401. https://doi.org/10.1002/bjs.9873
  42. Kusano C, Iwasaki M, Kaltenbach T, Conlin A, Oda I, Gotoda T. Should elderly patients undergo additional surgery after non-curative endoscopic resection for early gastric cancer? Long-term comparative outcomes. Am J Gastroenterol 2011;106:1064-1069. https://doi.org/10.1038/ajg.2011.49
  43. Kim YI, Kim HS, Kook MC, Cho SJ, Lee JY, Kim CG, et al. Discrepancy between clinical and final pathological evaluation findings in early gastric cancer patients treated with endoscopic submucosal dissection. J Gastric Cancer 2016;16:34-42. https://doi.org/10.5230/jgc.2016.16.1.34
  44. Abe S, Oda I, Suzuki H, Nonaka S, Yoshinaga S, Odagaki T, et al. Short- and long-term outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. Endoscopy 2013;45:703-707. https://doi.org/10.1055/s-0033-1344396
  45. Ahn JY, Park HJ, Park YS, Lee JH, Choi KS, Jeong KW, et al. Endoscopic resection for undifferentiatedtype early gastric cancer: immediate endoscopic outcomes and long-term survivals. Dig Dis Sci 2016;61:1158-1164. https://doi.org/10.1007/s10620-015-3988-y
  46. Kim JH, Kim YH, Jung DH, Jeon HH, Lee YC, Lee H, et al. Follow-up outcomes of endoscopic resection for early gastric cancer with undifferentiated histology. Surg Endosc 2014;28:2627-2633. https://doi.org/10.1007/s00464-014-3514-x
  47. Oka S, Tanaka S, Higashiyama M, Numata N, Sanomura Y, Yoshida S, et al. Clinical validity of the expanded criteria for endoscopic resection of undifferentiated-type early gastric cancer based on longterm outcomes. Surg Endosc 2014;28:639-647. https://doi.org/10.1007/s00464-013-3222-y
  48. Okada K, Fujisaki J, Yoshida T, Ishikawa H, Suganuma T, Kasuga A, et al. Long-term outcomes of endoscopic submucosal dissection for undifferentiated-type early gastric cancer. Endoscopy 2012;44:122-127. https://doi.org/10.1055/s-0031-1291486
  49. Park JC, Lee YK, Kim SY, Roh Y, Hahn KY, Shin SK, et al. Long-term outcomes of endoscopic submucosal dissection in comparison to surgery in undifferentiated-type intramucosal gastric cancer using propensity score analysis. Surg Endosc 2018;32:2046-2057. https://doi.org/10.1007/s00464-017-5901-6
  50. Suzuki S, Gotoda T, Hatta W, Oyama T, Kawata N, Takahashi A, et al. Survival benefit of additional surgery after non-curative endoscopic submucosal dissection for early gastric cancer: a propensity score matching analysis. Ann Surg Oncol 2017;24:3353-3360. https://doi.org/10.1245/s10434-017-6039-4
  51. Noh GY, Ku HR, Kim YJ, Park SC, Kim J, Han CJ, et al. Clinical outcomes of early gastric cancer with lymphovascular invasion or positive vertical resection margin after endoscopic submucosal dissection. Surg Endosc 2015;29:2583-2589. https://doi.org/10.1007/s00464-014-3973-0
  52. Choi JY, Jeon SW, Cho KB, Park KS, Kim ES, Park CK, et al. Non-curative endoscopic resection does not always lead to grave outcomes in submucosal invasive early gastric cancer. Surg Endosc 2015;29:1842-1849. https://doi.org/10.1007/s00464-014-3874-2
  53. Toya Y, Endo M, Nakamura S, Akasaka R, Kosaka T, Yanai S, et al. Clinical outcomes of non-curative endoscopic submucosal dissection with negative resected margins for gastric cancer. Gastrointest Endosc 2017;85:1218-1224. https://doi.org/10.1016/j.gie.2016.11.018
  54. Jung DH, Lee YC, Kim JH, Lee SK, Shin SK, Park JC, et al. Additive treatment improves survival in elderly patients after non-curative endoscopic resection for early gastric cancer. Surg Endosc 2017;31:1376-1382. https://doi.org/10.1007/s00464-016-5123-3
  55. Kawata N, Kakushima N, Takizawa K, Tanaka M, Makuuchi R, Tokunaga M, et al. Risk factors for lymph node metastasis and long-term outcomes of patients with early gastric cancer after non-curative endoscopic submucosal dissection. Surg Endosc 2017;31:1607-1616. https://doi.org/10.1007/s00464-016-5148-7
  56. Yano T, Ishido K, Tanabe S, Wada T, Azuma M, Kawanishi N, et al. Long-term outcomes of patients with early gastric cancer found to have lesions for which endoscopic treatment is not indicated on histopathological evaluation after endoscopic submucosal dissection. Surg Endosc 2018;32:1314-1323. https://doi.org/10.1007/s00464-017-5809-1
  57. Suzuki H, Oda I, Abe S, Sekiguchi M, Nonaka S, Yoshinaga S, et al. Clinical outcomes of early gastric cancer patients after noncurative endoscopic submucosal dissection in a large consecutive patient series. Gastric Cancer 2017;20:679-689. https://doi.org/10.1007/s10120-016-0651-z
  58. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N, et al. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg 1997;226:613-620. https://doi.org/10.1097/00000658-199711000-00006
  59. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999;230:170-178. https://doi.org/10.1097/00000658-199908000-00006
  60. Gouzi JL, Huguier M, Fagniez PL, Launois B, Flamant Y, Lacaine F, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 1989;209:162-166. https://doi.org/10.1097/00000658-198902000-00005
  61. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R, et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011;60:1449-1472. https://doi.org/10.1136/gut.2010.228254
  62. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMOESSO- ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi57-vi63. https://doi.org/10.1093/annonc/mdt344
  63. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19. https://doi.org/10.1007/s10120-016-0622-4
  64. Seevaratnam R, Bocicariu A, Cardoso R, Mahar A, Kiss A, Helyer L, et al. A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer 2012;15 Suppl 1:S60-S69. https://doi.org/10.1007/s10120-011-0110-9
  65. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15- year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-449. https://doi.org/10.1016/S1470-2045(10)70070-X
  66. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7:309-315. https://doi.org/10.1016/S1470-2045(06)70623-4
  67. Kitamura K, Yamaguchi T, Nishida S, Yamamoto K, Ichikawa D, Okamoto K, et al. The operative indications for proximal gastrectomy in patients with gastric cancer in the upper third of the stomach. Surg Today 1997;27:993-998. https://doi.org/10.1007/BF02385777
  68. Yoo CH, Sohn BH, Han WK, Pae WK. Long-term results of proximal and total gastrectomy for adenocarcinoma of the upper third of the stomach. Cancer Res Treat 2004;36:50-55. https://doi.org/10.4143/crt.2004.36.1.50
  69. An JY, Youn HG, Choi MG, Noh JH, Sohn TS, Kim S. The difficult choice between total and proximal gastrectomy in proximal early gastric cancer. Am J Surg 2008;196:587-591. https://doi.org/10.1016/j.amjsurg.2007.09.040
  70. Ahn SH, Lee JH, Park DJ, Kim HH. Comparative study of clinical outcomes between laparoscopy-assisted proximal gastrectomy (LAPG) and laparoscopy-assisted total gastrectomy (LATG) for proximal gastric cancer. Gastric Cancer 2013;16:282-289. https://doi.org/10.1007/s10120-012-0178-x
  71. Masuzawa T, Takiguchi S, Hirao M, Imamura H, Kimura Y, Fujita J, et al. Comparison of perioperative and long-term outcomes of total and proximal gastrectomy for early gastric cancer: a multi-institutional retrospective study. World J Surg 2014;38:1100-1106. https://doi.org/10.1007/s00268-013-2370-5
  72. Huh YJ, Lee HJ, Oh SY, Lee KG, Yang JY, Ahn HS, et al. Clinical outcome of modified laparoscopy-assisted proximal gastrectomy compared to conventional proximal gastrectomy or total gastrectomy for upper-third early gastric cancer with special references to postoperative reflux esophagitis. J Gastric Cancer 2015;15:191-200. https://doi.org/10.5230/jgc.2015.15.3.191
  73. Jung DH, Lee Y, Kim DW, Park YS, Ahn SH, Park DJ, et al. Laparoscopic proximal gastrectomy with double tract reconstruction is superior to laparoscopic total gastrectomy for proximal early gastric cancer. Surg Endosc 2017;31:3961-3969. https://doi.org/10.1007/s00464-017-5429-9
  74. Toyomasu Y, Ogata K, Suzuki M, Yanoma T, Kimura A, Kogure N, et al. Restoration of gastrointestinal motility ameliorates nutritional deficiencies and body weight loss of patients who undergo laparoscopyassisted proximal gastrectomy. Surg Endosc 2017;31:1393-1401. https://doi.org/10.1007/s00464-016-5127-z
  75. Yoo CH, Sohn BH, Han WK, Pae WK. Proximal gastrectomy reconstructed by jejunal pouch interposition for upper third gastric cancer: prospective randomized study. World J Surg 2005;29:1592-1599. https://doi.org/10.1007/s00268-005-7793-1
  76. Ohashi M, Morita S, Fukagawa T, Oda I, Kushima R, Katai H. Functional advantages of proximal gastrectomy with jejunal interposition over total gastrectomy with Roux-en-Y esophagojejunostomy for early gastric cancer. World J Surg 2015;39:2726-2733. https://doi.org/10.1007/s00268-015-3180-8
  77. Ushimaru Y, Fujiwara Y, Shishido Y, Yanagimoto Y, Moon JH, Sugimura K, et al. Clinical outcomes of gastric cancer patients who underwent proximal or total gastrectomy: a propensity score-matched analysis. World J Surg 2018;42:1477-1484. https://doi.org/10.1007/s00268-017-4306-y
  78. Takiguchi N, Takahashi M, Ikeda M, Inagawa S, Ueda S, Nobuoka T, et al. Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45): a nationwide multi-institutional study. Gastric Cancer 2015;18:407-416. https://doi.org/10.1007/s10120-014-0377-8
  79. Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukuda K, et al. Evaluation of a pyloruspreserving gastrectomy for patients preoperatively diagnosed with early gastric cancer located in the middle third of the stomach. Surg Today 2010;40:228-233. https://doi.org/10.1007/s00595-009-4043-4
  80. Suh YS, Han DS, Kong SH, Kwon S, Shin CI, Kim WH, et al. Laparoscopy-assisted pylorus-preserving gastrectomy is better than laparoscopy-assisted distal gastrectomy for middle-third early gastric cancer. Ann Surg 2014;259:485-493. https://doi.org/10.1097/SLA.0b013e318294d142
  81. Xiao XM, Gaol C, Yin W, Yu WH, Qi F, Liu T. Pylorus-preserving versus distal subtotal gastrectomy for surgical treatment of early gastric cancer: a meta-analysis. Hepatogastroenterology 2014;61:870-879.
  82. Aizawa M, Honda M, Hiki N, Kinoshita T, Yabusaki H, Nunobe S, et al. Oncological outcomes of functionpreserving gastrectomy for early gastric cancer: a multicenter propensity score matched cohort analysis comparing pylorus-preserving gastrectomy versus conventional distal gastrectomy. Gastric Cancer 2017;20:709-717. https://doi.org/10.1007/s10120-016-0644-y
  83. Nakane Y, Akehira K, Inoue K, Iiyama H, Sato M, Masuya Y, et al. Postoperative evaluation of pyloruspreserving gastrectomy for early gastric cancer. Hepatogastroenterology 2000;47:590-595.
  84. Smith JW, Brennan MF. Surgical treatment of gastric cancer. Proximal, mid, and distal stomach. Surg Clin North Am 1992;72:381-399. https://doi.org/10.1016/S0039-6109(16)45685-9
  85. Cai Z, Zhou Y, Wang C, Yin Y, Yin Y, Shen C, et al. Optimal reconstruction methods after distal gastrectomy for gastric cancer: a systematic review and network meta-analysis. Medicine (Baltimore) 2018;97:e10823. https://doi.org/10.1097/MD.0000000000010823
  86. Lee MS, Ahn SH, Lee JH, Park DJ, Lee HJ, Kim HH, et al. What is the best reconstruction method after distal gastrectomy for gastric cancer? Surg Endosc 2012;26:1539-1547. https://doi.org/10.1007/s00464-011-2064-8
  87. Inokuchi M, Kojima K, Yamada H, Kato K, Hayashi M, Motoyama K, et al. Long-term outcomes of Rouxen- Y and Billroth-I reconstruction after laparoscopic distal gastrectomy. Gastric Cancer 2013;16:67-73. https://doi.org/10.1007/s10120-012-0154-5
  88. Tanigawa N, Nomura E, Lee SW, Kaminishi M, Sugiyama M, Aikou T, et al. Current state of gastric stump carcinoma in Japan: based on the results of a nationwide survey. World J Surg 2010;34:1540-1547. https://doi.org/10.1007/s00268-010-0505-5
  89. Folli S, Morgagni P, Roviello F, De Manzoni G, Marrelli D, Saragoni L, et al. Risk factors for lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC). Jpn J Clin Oncol 2001;31:495-499. https://doi.org/10.1093/jjco/hye107
  90. Degiuli M, Calvo F. Survival of early gastric cancer in a specialized European center. Which lymphadenectomy is necessary? World J Surg 2006;30:2193-2203. https://doi.org/10.1007/s00268-006-0179-1
  91. Shimoyama S, Yasuda H, Mafune K, Kaminishi M. Indications of a minimized scope of lymphadenectomy for submucosal gastric cancer. Ann Surg Oncol 2002;9:625-631. https://doi.org/10.1007/BF02574477
  92. Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002;131:401-407. https://doi.org/10.1067/msy.2002.121891
  93. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-563. https://doi.org/10.1002/bjs.5353
  94. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg 2017;265:277-283. https://doi.org/10.1097/SLA.0000000000001814
  95. Brar SS, Seevaratnam R, Cardoso R, Law C, Helyer L, Coburn N. A systematic review of spleen and pancreas preservation in extended lymphadenectomy for gastric cancer. Gastric Cancer 2012;15 Suppl 1:S89-S99. https://doi.org/10.1007/s10120-011-0087-4
  96. Yang K, Chen XZ, Hu JK, Zhang B, Chen ZX, Chen JP. Effectiveness and safety of splenectomy for gastric carcinoma: a meta-analysis. World J Gastroenterol 2009;15:5352-5359. https://doi.org/10.3748/wjg.15.5352
  97. Lee IS, Ahn JY, Yook JH, Kim BS. Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma. World J Surg Oncol 2017;15:28. https://doi.org/10.1186/s12957-016-1088-x
  98. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-1669. https://doi.org/10.1056/NEJMoa022343
  99. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006;7:644-651. https://doi.org/10.1016/S1470-2045(06)70766-5
  100. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007;246:992-1000. https://doi.org/10.1097/SLA.0b013e31815c4037
  101. Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg 2015;102:341-348. https://doi.org/10.1002/bjs.9764
  102. Davies AR, Sandhu H, Pillai A, Sinha P, Mattsson F, Forshaw MJ, et al. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg 2014;101:511-517. https://doi.org/10.1002/bjs.9456
  103. Zheng Z, Cai J, Yin J, Zhang J, Zhang ZT, Wang KL. Transthoracic versus abdominal-transhiatal resection for treating Siewert type II/III adenocarcinoma of the esophagogastric junction: a meta-analysis. Int J Clin Exp Med 2015;8:17167-17182.
  104. Kitano S, Shiraishi N, Fujii K, Yasuda K, Inomata M, Adachi Y. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery 2002;131:S306-S311. https://doi.org/10.1067/msy.2002.120115
  105. Hayashi H, Ochiai T, Shimada H, Gunji Y. Prospective randomized study of open versus laparoscopyassisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surg Endosc 2005;19:1172-1176. https://doi.org/10.1007/s00464-004-8207-4
  106. Kim YW, Baik YH, Yun YH, Nam BH, Kim DH, Choi IJ, et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 2008;248:721-727. https://doi.org/10.1097/SLA.0b013e318185e62e
  107. Kim YW, Yoon HM, Yun YH, Nam BH, Eom BW, Baik YH, et al. Long-term outcomes of laparoscopyassisted distal gastrectomy for early gastric cancer: result of a randomized controlled trial (COACT 0301). Surg Endosc 2013;27:4267-4276. https://doi.org/10.1007/s00464-013-3037-x
  108. Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. Surg Endosc 2005;19:168-173. https://doi.org/10.1007/s00464-004-8808-y
  109. Sakuramoto S, Yamashita K, Kikuchi S, Futawatari N, Katada N, Watanabe M, et al. Laparoscopy versus open distal gastrectomy by expert surgeons for early gastric cancer in Japanese patients: short-term clinical outcomes of a randomized clinical trial. Surg Endosc 2013;27:1695-1705. https://doi.org/10.1007/s00464-012-2658-9
  110. Takiguchi S, Fujiwara Y, Yamasaki M, Miyata H, Nakajima K, Sekimoto M, et al. Laparoscopy-assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study. World J Surg 2013;37:2379-2386. https://doi.org/10.1007/s00268-013-2121-7
  111. Yamashita K, Sakuramoto S, Kikuchi S, Futawatari N, Katada N, Hosoda K, et al. Laparoscopic versus open distal gastrectomy for early gastric cancer in Japan: long-term clinical outcomes of a randomized clinical trial. Surg Today 2016;46:741-749. https://doi.org/10.1007/s00595-015-1221-4
  112. Lu C, Zhou S, Peng Z, Chen L. Quality of D2 lymphadenectomy for advanced gastric cancer: is laparoscopic-assisted distal gastrectomy as effective as open distal gastrectomy? Surg Endosc 2015;29:1537-1544. https://doi.org/10.1007/s00464-014-3838-6
  113. Zou ZH, Zhao LY, Mou TY, Hu YF, Yu J, Liu H, et al. Laparoscopic vs open D2 gastrectomy for locally advanced gastric cancer: a meta-analysis. World J Gastroenterol 2014;20:16750-16764. https://doi.org/10.3748/wjg.v20.i44.16750
  114. Choi YY, Bae JM, An JY, Hyung WJ, Noh SH. Laparoscopic gastrectomy for advanced gastric cancer: are the long-term results comparable with conventional open gastrectomy? A systematic review and metaanalysis. J Surg Oncol 2013;108:550-556. https://doi.org/10.1002/jso.23438
  115. Chen K, Xu XW, Mou YP, Pan Y, Zhou YC, Zhang RC, et al. Systematic review and meta-analysis of laparoscopic and open gastrectomy for advanced gastric cancer. World J Surg Oncol 2013;11:182. https://doi.org/10.1186/1477-7819-11-182
  116. Martinez-Ramos D, Miralles-Tena JM, Cuesta MA, Escrig-Sos J, Van der Peet D, Hoashi JS, et al. Laparoscopy versus open surgery for advanced and resectable gastric cancer: a meta-analysis. Rev Esp Enferm Dig 2011;103:133-141.
  117. Wang W, Li Z, Tang J, Wang M, Wang B, Xu Z. Laparoscopic versus open total gastrectomy with D2 dissection for gastric cancer: a meta-analysis. J Cancer Res Clin Oncol 2013;139:1721-1734. https://doi.org/10.1007/s00432-013-1462-9
  118. Ding J, Liao GQ, Liu HL, Liu S, Tang J. Meta-analysis of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer. J Surg Oncol 2012;105:297-303. https://doi.org/10.1002/jso.22098
  119. Park YK, Yoon HM, Kim YW, Park JY, Ryu KW, Lee YJ, et al. Laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer: results from a randomized phase II multicenter clinical trial (COACT 1001). Ann Surg 2018;267:638-645. https://doi.org/10.1097/SLA.0000000000002168
  120. Huscher CG, Mingoli A, Sgarzini G, Sansonetti A, Di Paola M, Recher A, et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann Surg 2005;241:232-237. https://doi.org/10.1097/01.sla.0000151892.35922.f2
  121. Cai J, Wei D, Gao CF, Zhang CS, Zhang H, Zhao T. A prospective randomized study comparing open versus laparoscopy-assisted D2 radical gastrectomy in advanced gastric cancer. Dig Surg 2011;28:331-337. https://doi.org/10.1159/000330782
  122. Hur H, Lee HY, Lee HJ, Kim MC, Hyung WJ, Park YK, et al. Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer: the protocol of the KLASS-02 multicenter randomized controlled clinical trial. BMC Cancer 2015;15:355. https://doi.org/10.1186/s12885-015-1365-z
  123. Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol 2016;34:1350-1357. https://doi.org/10.1200/JCO.2015.63.7215
  124. Cui M, Li Z, Xing J, Yao Z, Liu M, Chen L, et al. A prospective randomized clinical trial comparing D2 dissection in laparoscopic and open gastrectomy for gastric cancer. Med Oncol 2015;32:241. https://doi.org/10.1007/s12032-015-0680-1
  125. Inaki N, Etoh T, Ohyama T, Uchiyama K, Katada N, Koeda K, et al. A multi-institutional, prospective, phase II feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). World J Surg 2015;39:2734-2741. https://doi.org/10.1007/s00268-015-3160-z
  126. Suda K, Man-I M, Ishida Y, Kawamura Y, Satoh S, Uyama I. Potential advantages of robotic radical gastrectomy for gastric adenocarcinoma in comparison with conventional laparoscopic approach: a single institutional retrospective comparative cohort study. Surg Endosc 2015;29:673-685. https://doi.org/10.1007/s00464-014-3718-0
  127. Yang SY, Roh KH, Kim YN, Cho M, Lim SH, Son T, et al. Surgical outcomes after open, laparoscopic, and robotic gastrectomy for gastric cancer. Ann Surg Oncol 2017;24:1770-1777. https://doi.org/10.1245/s10434-017-5851-1
  128. Song J, Oh SJ, Kang WH, Hyung WJ, Choi SH, Noh SH. Robot-assisted gastrectomy with lymph node dissection for gastric cancer: lessons learned from an initial 100 consecutive procedures. Ann Surg 2009;249:927-932. https://doi.org/10.1097/01.sla.0000351688.64999.73
  129. Murphy R, Evennett NJ, Clarke MG, Robinson SJ, Humphreys L, Jones B, et al. Sleeve gastrectomy versus Roux-en-Y gastric bypass for type 2 diabetes and morbid obesity: double-blind randomised clinical trial protocol. BMJ Open 2016;6:e011416. https://doi.org/10.1136/bmjopen-2016-011416
  130. Noshiro H, Ikeda O, Urata M. Robotically-enhanced surgical anatomy enables surgeons to perform distal gastrectomy for gastric cancer using electric cautery devices alone. Surg Endosc 2014;28:1180-1187. https://doi.org/10.1007/s00464-013-3304-x
  131. Son T, Lee JH, Kim YM, Kim HI, Noh SH, Hyung WJ. Robotic spleen-preserving total gastrectomy for gastric cancer: comparison with conventional laparoscopic procedure. Surg Endosc 2014;28:2606-2615. https://doi.org/10.1007/s00464-014-3511-0
  132. Junfeng Z, Yan S, Bo T, Yingxue H, Dongzhu Z, Yongliang Z, et al. Robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: comparison of surgical performance and short-term outcomes. Surg Endosc 2014;28:1779-1787. https://doi.org/10.1007/s00464-013-3385-6
  133. Lim DH, Kim DY, Kang MK, Kim YI, Kang WK, Park CK, et al. Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view. Br J Cancer 2004;91:11-17. https://doi.org/10.1038/sj.bjc.6601896
  134. Al-Batran SE, Homann N, Schmalenberg H, Kopp HG, Haag GM, Luley KB, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4- AIO): a multicenter, randomized phase 3 trial. J Clin Oncol 2017;35 15_suppl:4004. https://doi.org/10.1200/JCO.2017.35.15_suppl.4004
  135. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. https://doi.org/10.1056/NEJMoa055531
  136. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  137. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
  138. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma - 2nd English edition -. Gastric Cancer 1998;1:10-24. https://doi.org/10.1007/PL00011681
  139. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, eds. AJCC Cancer Staging Manual. 6th ed. Chicago (IL): Springer, 2002.
  140. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393. https://doi.org/10.1200/JCO.2011.36.5908
  141. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-1396. https://doi.org/10.1016/S1470-2045(14)70473-5
  142. Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, et al. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Radiother Oncol 2012;104:367-373. https://doi.org/10.1016/j.radonc.2012.08.017
  143. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11. https://doi.org/10.1016/0360-3016(82)90375-3
  144. Moertel CG, Childs DS, O'Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984;2:1249-1254. https://doi.org/10.1200/JCO.1984.2.11.1249
  145. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990;19:1357-1362. https://doi.org/10.1016/0360-3016(90)90344-J
  146. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730. https://doi.org/10.1056/NEJMoa010187
  147. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOGdirected intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-2333. https://doi.org/10.1200/JCO.2011.36.7136
  148. Shim JH, Song KY, Jeon HM, Park CH, Jacks LM, Gonen M, et al. Is gastric cancer different in Korea and the United States? Impact of tumor location on prognosis. Ann Surg Oncol 2014;21:2332-2339. https://doi.org/10.1245/s10434-014-3608-7
  149. Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010;28:2430-2436. https://doi.org/10.1200/JCO.2009.26.9654
  150. Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 2010;65:1009-1021. https://doi.org/10.1007/s00280-010-1256-6
  151. Kim TH, Park SR, Ryu KW, Kim YW, Bae JM, Lee JH, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys 2012;84:e585-e592. https://doi.org/10.1016/j.ijrobp.2012.07.2378
  152. Kwon HC, Kim MC, Kim KH, Jang JS, Oh SY, Kim SH, et al. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol 2010;6:278-285. https://doi.org/10.1111/j.1743-7563.2010.01331.x
  153. Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30:268-273.
  154. Zhu WG, Xua DF, Pu J, Zong CD, Li T, Tao GZ, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 2012;104:361-366. https://doi.org/10.1016/j.radonc.2012.08.024
  155. Dai Q, Jiang L, Lin RJ, Wei KK, Gan LL, Deng CH, et al. Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: a meta-analysis of randomized controlled trials. J Surg Oncol 2015;111:277-284. https://doi.org/10.1002/jso.23795
  156. Huang YY, Yang Q, Zhou SW, Wei Y, Chen YX, Xie DR, et al. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a metaanalysis. PLoS One 2013;8:e68939. https://doi.org/10.1371/journal.pone.0068939
  157. Min C, Bangalore S, Jhawar S, Guo Y, Nicholson J, Formenti SC, et al. Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: a meta-analysis of randomized trials. Oncology 2014;86:79-85. https://doi.org/10.1159/000354641
  158. Soon YY, Leong CN, Tey JC, Tham IW, Lu JJ. Postoperative chemo-radiotherapy versus chemotherapy for resected gastric cancer: a systematic review and meta-analysis. J Med Imaging Radiat Oncol 2014;58:483-496. https://doi.org/10.1111/1754-9485.12190
  159. Valentini V, Cellini F, Minsky BD, Mattiucci GC, Balducci M, D'Agostino G, et al. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. Radiother Oncol 2009;92:176-183. https://doi.org/10.1016/j.radonc.2009.06.014
  160. Zhou ML, Kang M, Li GC, Guo XM, Zhang Z. Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World J Surg Oncol 2016;14:209. https://doi.org/10.1186/s12957-016-0957-7
  161. Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol 2015;33:3130-3136. https://doi.org/10.1200/JCO.2014.58.3930
  162. Yu JI, Lim DH, Ahn YC, Lee J, Kang WK, Park SH, et al. Effects of adjuvant radiotherapy on completely resected gastric cancer: a radiation oncologist's view of the ARTIST randomized phase III trial. Radiother Oncol 2015;117:171-177. https://doi.org/10.1016/j.radonc.2015.08.009
  163. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-1721. https://doi.org/10.1200/JCO.2010.33.0597
  164. Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, et al. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501). J Clin Oncol 2018;36 15_suppl:4046. https://doi.org/10.1200/JCO.2018.36.15_suppl.4046
  165. Klevebro F, Alexandersson von Dobeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 2016;27:660-667. https://doi.org/10.1093/annonc/mdw010
  166. Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol 2017;24:2252-2258. https://doi.org/10.1245/s10434-017-5830-6
  167. Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur J Cancer 2017;81:183-190. https://doi.org/10.1016/j.ejca.2017.04.027
  168. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856. https://doi.org/10.1200/JCO.2008.17.0506
  169. Fu T, Bu ZD, Li ZY, Zhang LH, Wu XJ, Wu AW, et al. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer 2015;15:322. https://doi.org/10.1186/s12885-015-1341-7
  170. Kumagai K, Rouvelas I, Tsai JA, Mariosa D, Lind PA, Lindblad M, et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis. Eur J Surg Oncol 2015;41:282-294. https://doi.org/10.1016/j.ejso.2014.11.039
  171. Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer 2013;49:3149-3158. https://doi.org/10.1016/j.ejca.2013.05.029
  172. Hofheinz R, Clouth J, Borchardt-Wagner J, Wagner U, Weidling E, Jen MH, et al. Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany. BMC Cancer 2016;16:937. https://doi.org/10.1186/s12885-016-2975-9
  173. Hsu JT, Liao JA, Chuang HC, Chen TD, Chen TH, Kuo CJ, et al. Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer. BMC Palliat Care 2017;16:19. https://doi.org/10.1186/s12904-017-0192-1
  174. Dong Y, Ma S, Yang S, Luo F, Wang Z, Guo F. Non-curative surgery for patients with gastric cancer with local peritoneal metastasis: a retrospective cohort study. Medicine (Baltimore) 2016;95:e5607. https://doi.org/10.1097/MD.0000000000005607
  175. Yang K, Liu K, Zhang WH, Lu ZH, Chen XZ, Chen XL, et al. The value of palliative gastrectomy for gastric cancer patients with intraoperatively proven peritoneal seeding. Medicine (Baltimore) 2015;94:e1051. https://doi.org/10.1097/MD.0000000000001051
  176. Naka T, Iwahashi M, Nakamori M, Nakamura M, Ojima T, Iida T, et al. The evaluation of surgical treatment for gastric cancer patients with noncurative resection. Langenbecks Arch Surg 2012;397:959-966. https://doi.org/10.1007/s00423-012-0906-z
  177. Sougioultzis S, Syrios J, Xynos ID, Bovaretos N, Kosmas C, Sarantonis J, et al. Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis. Eur J Surg Oncol 2011;37:312-318. https://doi.org/10.1016/j.ejso.2011.01.019
  178. Zhu G, Zhang M, Zhang H, Gao H, Xue Y. Survival predictors of patients with gastric cancer with peritoneal metastasis. Hepatogastroenterology 2010;57:997-1000.
  179. Kim KH, Lee KW, Baek SK, Chang HJ, Kim YJ, Park DJ, et al. Survival benefit of gastrectomy $\pm$ metastasectomy in patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer 2011;14:130-138. https://doi.org/10.1007/s10120-011-0015-7
  180. Li SC, Lee CH, Hung CL, Wu JC, Chen JH. Surgical resection of metachronous hepatic metastases from gastric cancer improves long-term survival: a population-based study. PLoS One 2017;12:e0182255. https://doi.org/10.1371/journal.pone.0182255
  181. Markar SR, Mackenzie H, Mikhail S, Mughal M, Preston SR, Maynard ND, et al. Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England. Gastric Cancer 2017;20:379-386. https://doi.org/10.1007/s10120-016-0604-6
  182. Saito A, Korenaga D, Sakaguchi Y, Ohno S, Ichiyoshi Y, Sugimachi K. Surgical treatment for gastric carcinomas with concomitant hepatic metastasis. Hepatogastroenterology 1996;43:560-564.
  183. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 2008;19:1146-1153. https://doi.org/10.1093/annonc/mdn026
  184. Okumura Y, Yamashita H, Aikou S, Yagi K, Yamagata Y, Nishida M, et al. Palliative distal gastrectomy offers no survival benefit over gastrojejunostomy for gastric cancer with outlet obstruction: retrospective analysis of an 11-year experience. World J Surg Oncol 2014;12:364. https://doi.org/10.1186/1477-7819-12-364
  185. Tokunaga M, Terashima M, Tanizawa Y, Bando E, Kawamura T, Yasui H, et al. Survival benefit of palliative gastrectomy in gastric cancer patients with peritoneal metastasis. World J Surg 2012;36:2637-2643. https://doi.org/10.1007/s00268-012-1721-y
  186. Park SH, Kim JH, Park JM, Park SS, Kim SJ, Kim CS, et al. Value of nonpalliative resection as a therapeutic and pre-emptive operation for metastatic gastric cancer. World J Surg 2009;33:303-311. https://doi.org/10.1007/s00268-008-9829-9
  187. Kokkola A, Louhimo J, Puolakkainen P. Does non-curative gastrectomy improve survival in patients with metastatic gastric cancer? J Surg Oncol 2012;106:193-196. https://doi.org/10.1002/jso.23066
  188. Lupascu C, Andronic D, Ursulescu C, Vasiluta C, Raileanu G, Georgescu St, et al. Palliative gastrectomy in patients with stage IV gastric cancer--our recent experience. Chirurgia (Bucur) 2010;105:473-476.
  189. Yoshikawa T, Kanari M, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, et al. Should gastric cancer with peritoneal metastasis be treated surgically? Hepatogastroenterology 2003;50:1712-1715.
  190. Rafique M, Adachi W, Kajikawa S, Kobayashi M, Koike S, Kuroda T. Management of gastric cancer patients with synchronous hepatic metastasis: a retrospective study. Hepatogastroenterology 1995;42:666-671.
  191. He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Jin Y, et al. The role of non-curative surgery in incurable, asymptomatic advanced gastric cancer. PLoS One 2013;8:e83921. https://doi.org/10.1371/journal.pone.0083921
  192. Sun J, Song Y, Wang Z, Chen X, Gao P, Xu Y, et al. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer 2013;13:577. https://doi.org/10.1186/1471-2407-13-577
  193. Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res 2014;34:2079-2085.
  194. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016;17:309-318. https://doi.org/10.1016/S1470-2045(15)00553-7
  195. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41. https://doi.org/10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
  196. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 1995;71:587-591. https://doi.org/10.1038/bjc.1995.114
  197. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168. https://doi.org/10.1023/A:1008243606668
  198. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909. https://doi.org/10.1200/JCO.2005.05.0245
  199. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46. https://doi.org/10.1056/NEJMoa073149
  200. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/ cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673. https://doi.org/10.1093/annonc/mdn717
  201. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:1529-1534. https://doi.org/10.1093/annonc/mdp047
  202. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-1069. https://doi.org/10.1016/S1470-2045(09)70259-1
  203. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010;28:1547-1553. https://doi.org/10.1200/JCO.2009.25.4706
  204. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442. https://doi.org/10.1200/JCO.2007.13.9378
  205. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 2015;26:141-148. https://doi.org/10.1093/annonc/mdu472
  206. Ryu MH, Park YI, Chung IJ, Lee KW, Oh HS, Lee KH, et al. Phase III trial of s-1 plus oxaliplatin (SOX) vs s-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOPP study. J Clin Oncol 2016;34 15_suppl:4015. https://doi.org/10.1200/JCO.2016.67.2980
  207. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006;24:4991-4997. https://doi.org/10.1200/JCO.2006.06.8429
  208. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
  209. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314. https://doi.org/10.1016/j.ejca.2011.06.002
  210. Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-1518. https://doi.org/10.1200/JCO.2011.39.4585
  211. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15:78-86. https://doi.org/10.1016/S1470-2045(13)70549-7
  212. Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol 2013;24:2850-2854. https://doi.org/10.1093/annonc/mdt351
  213. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013;31:4438-4444. https://doi.org/10.1200/JCO.2012.48.5805
  214. Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, et al. A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01). Oncologist 2019;24:18-e24. https://doi.org/10.1634/theoncologist.2018-0142
  215. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-39. https://doi.org/10.1016/S0140-6736(13)61719-5
  216. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-1235. https://doi.org/10.1016/S1470-2045(14)70420-6
  217. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409-413. https://doi.org/10.1126/science.aan6733
  218. Lee MJ, Hwang IG, Jang JS, Choi JH, Park BB, Chang MH, et al. Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies. Cancer Res Treat 2012;44:235-241. https://doi.org/10.4143/crt.2012.44.4.235
  219. Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, et al. Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy. Oncologist 2017;22:1463-1469. https://doi.org/10.1634/theoncologist.2017-0158
  220. Choi IS, Choi M, Lee JH, Kim JH, Suh KJ, Lee JY, et al. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: a population-based outcomes study. PLoS One 2018;13:e0198544. https://doi.org/10.1371/journal.pone.0198544
  221. Tabernero J, Shitara K, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. LBA-002 Overall survival results from a phase III trial of trifluridine/tipitacil vs. placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). Ann Oncol 2018;29:mdy208.001.
  222. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol 2016;34:1448-1454. https://doi.org/10.1200/JCO.2015.63.5995
  223. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:2461-2471. https://doi.org/10.1016/S0140-6736(17)31827-5
  224. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17:717-726. https://doi.org/10.1016/S1470-2045(16)00175-3
  225. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4:e180013. https://doi.org/10.1001/jamaoncol.2018.0013
  226. Depypere L, Lerut T, Moons J, Coosemans W, Decker G, Van Veer H, et al. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road. Dis Esophagus 2017;30:1-8.
  227. Hingorani M, Dixit S, Johnson M, Plested V, Alty K, Colley P, et al. Palliative radiotherapy in the presence of well-controlled metastatic disease after initial chemotherapy may prolong survival in patients with metastatic esophageal and gastric cancer. Cancer Res Treat 2015;47:706-717. https://doi.org/10.4143/crt.2014.174
  228. Sun J, Sun YH, Zeng ZC, Qin XY, Zeng MS, Chen B, et al. Consideration of the role of radiotherapy for abdominal lymph node metastases in patients with recurrent gastric cancer. Int J Radiat Oncol Biol Phys 2010;77:384-391. https://doi.org/10.1016/j.ijrobp.2009.05.019
  229. Tey J, Back MF, Shakespeare TP, Mukherjee RK, Lu JJ, Lee KM, et al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 2007;67:385-388. https://doi.org/10.1016/j.ijrobp.2006.08.070
  230. Tey J, Choo BA, Leong CN, Loy EY, Wong LC, Lim K, et al. Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era. Medicine (Baltimore) 2014;93:e118. https://doi.org/10.1097/MD.0000000000000118
  231. Yoshikawa T, Tsuburaya A, Hirabayashi N, Yoshida K, Nagata N, Kodera Y, et al. A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma. Cancer Chemother Pharmacol 2009;64:1071-1077. https://doi.org/10.1007/s00280-009-0963-3
  232. Kim WH, Park CK, Kim YB, Kim YW, Kim HG, Bae HI, et al. A standardized pathology report for gastric cancer. Korean J Pathol 2005;39:106-113.
  233. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC Press, 2010.
  234. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49. https://doi.org/10.1111/apm.1965.64.1.31
  235. Iacobuzio-Donahue CA, Montgomery EA. Gastrointestinal and Liver Pathology E-Book: a Volume in the Series: Foundations in Diagnostic Pathology: Elsevier Health Sciences. 2nd ed. Philadelphia (PA): Elsevier, 2012.
  236. Nakashima Y, Yao T, Hirahashi M, Aishima S, Kakeji Y, Maehara Y, et al. Nuclear atypia grading score is a useful prognostic factor in papillary gastric adenocarcinoma. Histopathology 2011;59:841-849. https://doi.org/10.1111/j.1365-2559.2011.04035.x
  237. Nakamura K, Sugano H, Takagi K. Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gan 1968;59:251-258.
  238. Sugano H, Nakamura K, Kato Y. Pathological studies of human gastric cancer. Acta Pathol Jpn 1982;32 Suppl 2:329-347.
  239. Kim JM, Sohn JH, Cho MY, Kim WH, Chang HK, Jung ES, et al. Pre- and post-ESD discrepancies in clinicopathologic criteria in early gastric cancer: the NECA-Korea ESD for early gastric cancer prospective study (N-Keep). Gastric Cancer 2016;19:1104-1113. https://doi.org/10.1007/s10120-015-0570-4
  240. Shibata A, Longacre TA, Puligandla B, Parsonnet J, Habel LA. Histological classification of gastric adenocarcinoma for epidemiological research: concordance between pathologists. Cancer Epidemiol Biomarkers Prev 2001;10:75-78.
  241. Flucke U, Monig SP, Baldus SE, Zirbes TK, Bollschweiler E, Thiele J, et al. Differences between biopsy- or specimen-related Lauren and World Health Organization classification in gastric cancer. World J Surg 2002;26:137-140. https://doi.org/10.1007/s00268-001-0195-0
  242. Mita T, Shimoda T. Risk factors for lymph node metastasis of submucosal invasive differentiated type gastric carcinoma: clinical significance of histological heterogeneity. J Gastroenterol 2001;36:661-668. https://doi.org/10.1007/s005350170028
  243. Takizawa K, Ono H, Kakushima N, Tanaka M, Hasuike N, Matsubayashi H, et al. Risk of lymph node metastases from intramucosal gastric cancer in relation to histological types: how to manage the mixed histological type for endoscopic submucosal dissection. Gastric Cancer 2013;16:531-536. https://doi.org/10.1007/s10120-012-0220-z
  244. Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med 2016;140:1345-1363. https://doi.org/10.5858/arpa.2016-0331-CP
  245. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. https://doi.org/10.1111/j.1365-2559.2008.03028.x
  246. Provenzale D, Gupta S, Ahnen DJ, Blanco AM, Bray TH. NCCN cinical practice guidelines in oncology. Genetic/familial high-risk assessment: colorectal. Version 1. 2018 [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2018 [cited 2018 Jul 14]. Available from: https://www.nccn.org/ professionals/physician_gls/pdf/genetics_colon.pdf.
  247. Funkhouser WK Jr, Lubin IM, Monzon FA, Zehnbauer BA, Evans JP, Ogino S, et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn 2012;14:91-103. https://doi.org/10.1016/j.jmoldx.2011.11.001
  248. Serrano M, Lage P, Belga S, Filipe B, Francisco I, Rodrigues P, et al. Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome. Fam Cancer 2012;11:571-578. https://doi.org/10.1007/s10689-012-9550-6
  249. Buhard O, Suraweera N, Lectard A, Duval A, Hamelin R. Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis Markers 2004;20:251-257. https://doi.org/10.1155/2004/159347
  250. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209. https://doi.org/10.1038/nature13480
  251. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21:449-456. https://doi.org/10.1038/nm.3850
  252. Polom K, Marano L, Marrelli D, De Luca R, Roviello G, Savelli V, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg 2018;105:159-167. https://doi.org/10.1002/bjs.10663
  253. Ajani JA, D'Amico TA, Baggstrom M, Bentrem DJ, Chao J. NCCN clinical practice guidelines in oncology (NCCN guidelines). Gastric cancer, version 2. 2018 [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2018 [cited 2018 Jul 13]. Available from: https://www.nccn.org.
  254. Weiss LM, Chen YY. EBER in situ hybridization for Epstein-Barr virus. Methods Mol Biol 2013;999:223-230. https://doi.org/10.1007/978-1-62703-357-2_16
  255. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr viruspositive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009;137:824-833. https://doi.org/10.1053/j.gastro.2009.05.001
  256. Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut 2014;63:236-243. https://doi.org/10.1136/gutjnl-2013-304531
  257. Dako Agilent Pathology Solutions. PD-L1 IHC 22C3 pharmDx is FDA-Approved. Santa Clara (CA): Dako Agilent Pathology Solutions, 2018.
  258. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. https://doi.org/10.1016/S0140-6736(15)01281-7
  259. Kang KK, Hur H, Byun CS, Kim YB, Han SU, Cho YK. Conventional cytology is not beneficial for predicting peritoneal recurrence after curative surgery for gastric cancer: results of a prospective clinical study. J Gastric Cancer 2014;14:23-31. https://doi.org/10.5230/jgc.2014.14.1.23
  260. Cotte E, Peyrat P, Piaton E, Chapuis F, Rivoire M, Glehen O, et al. Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: results of EVOCAPE 2 multicentre prospective study. Eur J Surg Oncol 2013;39:707-714. https://doi.org/10.1016/j.ejso.2013.03.021
  261. Lee SD, Ryu KW, Eom BW, Lee JH, Kook MC, Kim YW. Prognostic significance of peritoneal washing cytology in patients with gastric cancer. Br J Surg 2012;99:397-403. https://doi.org/10.1002/bjs.7812
  262. Shimizu H, Imamura H, Ohta K, Miyazaki Y, Kishimoto T, Fukunaga M, et al. Usefulness of staging laparoscopy for advanced gastric cancer. Surg Today 2010;40:119-124. https://doi.org/10.1007/s00595-009-4017-6
  263. Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol 2010;17:3173-3180. https://doi.org/10.1245/s10434-010-1183-0
  264. La Torre M, Ferri M, Giovagnoli MR, Sforza N, Cosenza G, Giarnieri E, et al. Peritoneal wash cytology in gastric carcinoma. Prognostic significance and therapeutic consequences. Eur J Surg Oncol 2010;36:982-986. https://doi.org/10.1016/j.ejso.2010.06.007
  265. Jamel S, Markar SR, Malietzis G, Acharya A, Athanasiou T, Hanna GB. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis. Gastric Cancer 2018;21:10-18. https://doi.org/10.1007/s10120-017-0749-y
  266. Tustumi F, Bernardo WM, Dias AR, Ramos MF, Cecconello I, Zilberstein B, et al. Detection value of free cancer cells in peritoneal washing in gastric cancer: a systematic review and meta-analysis. Clinics (Sao Paulo) 2016;71:733-745. https://doi.org/10.6061/clinics/2016(12)10
  267. Pecqueux M, Fritzmann J, Adamu M, Thorlund K, Kahlert C, Reissfelder C, et al. Free intraperitoneal tumor cells and outcome in gastric cancer patients: a systematic review and meta-analysis. Oncotarget 2015;6:35564-35578. https://doi.org/10.18632/oncotarget.5595
  268. Leake PA, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer 2012;15 Suppl 1:S27-S37.
  269. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol 2006;7:935-943. https://doi.org/10.1016/S1470-2045(06)70940-8
  270. Taylor C, Munro AJ, Glynne-Jones R, Griffith C, Trevatt P, Richards M, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ 2010;340:c951. https://doi.org/10.1136/bmj.c951
  271. Lamb B, Green JS, Vincent C, Sevdalis N. Decision making in surgical oncology. Surg Oncol 2011;20:163-168. https://doi.org/10.1016/j.suronc.2010.07.007
  272. Basta YL, Baur OL, van Dieren S, Klinkenbijl JH, Fockens P, Tytgat KM. Is there a benefit of multidisciplinary cancer team meetings for patients with gastrointestinal malignancies? Ann Surg Oncol 2016;23:2430-2437. https://doi.org/10.1245/s10434-016-5178-3
  273. Basta YL, Bolle S, Fockens P, Tytgat KM. The value of multidisciplinary team meetings for patients with gastrointestinal malignancies: a systematic review. Ann Surg Oncol 2017;24:2669-2678. https://doi.org/10.1245/s10434-017-5833-3
  274. Du CZ, Li J, Cai Y, Sun YS, Xue WC, Gu J. Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy. World J Gastroenterol 2011;17:2013-2018. https://doi.org/10.3748/wjg.v17.i15.2013
  275. Oxenberg J, Papenfuss W, Esemuede I, Attwood K, Simunovic M, Kuvshinoff B, et al. Multidisciplinary cancer conferences for gastrointestinal malignancies result in measureable treatment changes: a prospective study of 149 consecutive patients. Ann Surg Oncol 2015;22:1533-1539. https://doi.org/10.1245/s10434-014-4163-y
  276. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v38-v49. https://doi.org/10.1093/annonc/mdw350
  277. Kunkler IH, Prescott RJ, Lee RJ, Brebner JA, Cairns JA, Fielding RG, et al. TELEMAM: a cluster randomised trial to assess the use of telemedicine in multi-disciplinary breast cancer decision making. Eur J Cancer 2007;43:2506-2514. https://doi.org/10.1016/j.ejca.2007.08.026
  278. Brar SS, Mahar AL, Helyer LK, Swallow C, Law C, Paszat L, et al. Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. JAMA Surg 2014;149:18-25. https://doi.org/10.1001/jamasurg.2013.3959
  279. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet 2016;388:2654-2664. https://doi.org/10.1016/S0140-6736(16)30354-3

Cited by

  1. Endoscopic submucosal dissection in the West vol.8, pp.3, 2019, https://doi.org/10.18528/ijgii190014
  2. Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant Ascites vol.19, pp.3, 2019, https://doi.org/10.5230/jgc.2019.19.e27
  3. Proposal of a New TNM Classification for Gastric Cancer: Focusing on pN3b and Cytology-Positive (CY1) Disease vol.19, pp.3, 2019, https://doi.org/10.5230/jgc.2019.19.e33
  4. ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER? vol.32, pp.4, 2019, https://doi.org/10.1590/0102-672020190001e1464
  5. Clinical Implications of Microsatellite Instability in Early Gastric Cancer vol.19, pp.4, 2019, https://doi.org/10.5230/jgc.2019.19.e38
  6. Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer vol.19, pp.4, 2019, https://doi.org/10.5230/jgc.2019.19.e39
  7. Feasibility of No Prophylactic Antibiotics Use in Patients Undergoing Total Laparoscopic Distal Gastrectomy for Gastric Carcinoma: a Propensity Score-Matched Case-Control Study vol.19, pp.4, 2019, https://doi.org/10.5230/jgc.2019.19.e41
  8. Oncometabolic surgery: Emergence and legitimacy for investigation vol.32, pp.2, 2019, https://doi.org/10.21147/j.issn.1000-9604.2020.02.12
  9. Predictive value of E-cadherin and EpCAM for detection of metastatic lymph node in early gastric cancer vol.32, pp.4, 2020, https://doi.org/10.21147/j.issn.1000-9604.2020.05.06
  10. Normal and Abnormal Postoperative Imaging Findings after Gastric Oncologic and Bariatric Surgery vol.21, pp.7, 2019, https://doi.org/10.3348/kjr.2019.0822
  11. Towards Personalization in the Curative Treatment of Gastric Cancer vol.10, 2019, https://doi.org/10.3389/fonc.2020.614907
  12. Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker vol.12, pp.1, 2020, https://doi.org/10.3390/cancers12010086
  13. Safety and Efficacy of Indocyanine Green Tracer-Guided Lymph Node Dissection During Laparoscopic Radical Gastrectomy in Patients With Gastric Cancer : A Randomized Clinical Trial vol.155, pp.4, 2019, https://doi.org/10.1001/jamasurg.2019.6033
  14. Relationship between neuropilin-1 expression and prognosis, according to gastric cancer histology vol.51, pp.2, 2019, https://doi.org/10.1007/s10735-020-09870-z
  15. Determining the current indications for endoscopic submucosal dissection in patients with Lauren mixed‐type early gastric cancer vol.35, pp.4, 2020, https://doi.org/10.1111/jgh.14846
  16. Chronological changes in quality of life and body composition after gastrectomy for locally advanced gastric cancer vol.98, pp.5, 2019, https://doi.org/10.4174/astr.2020.98.5.262
  17. Global updates in the treatment of gastric cancer: a systematic review. Part 2: perioperative management, multimodal therapies, new technologies, standardization of the surgical treatment and educatio vol.72, pp.2, 2019, https://doi.org/10.1007/s13304-020-00771-0
  18. Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched vol.20, pp.2, 2019, https://doi.org/10.5230/jgc.2020.20.e13
  19. Evaluation of Submucosal or Lymphovascular Invasion Detection Rates in Early Gastric Cancer Based on Pathology Section Interval vol.20, pp.2, 2020, https://doi.org/10.5230/jgc.2020.20.e14
  20. Advantages of Distal Subtotal Gastrectomy over Total Gastrectomy in the Quality of Life of Long-Term Gastric Cancer Survivors vol.20, pp.2, 2019, https://doi.org/10.5230/jgc.2020.20.e17
  21. A Recent Argument for the Use of Endoscopic Submucosal Dissection for Early Gastric Cancers vol.14, pp.4, 2020, https://doi.org/10.5009/gnl19194
  22. Operative safety of curative gastrectomy after endoscopic submucosal dissection (ESD) for early gastric cancer - 1:2 propensity score matching analysis: A retrospective single-center study (cohort stu vol.80, 2019, https://doi.org/10.1016/j.ijsu.2020.06.041
  23. From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancers—A Multidisciplinary Perspective vol.12, pp.8, 2020, https://doi.org/10.3390/cancers12082105
  24. Oncologic Benefit of Adjuvant Chemoradiation after D2 Gastrectomy: A Stepwise Hierarchical Pooled Analysis and Systematic Review vol.12, pp.8, 2020, https://doi.org/10.3390/cancers12082125
  25. Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer vol.20, pp.4, 2020, https://doi.org/10.3892/ol.2020.11893
  26. Modified controlling nutritional status score: A refined prognostic indicator depending on the stage of gastric cancer vol.34, 2019, https://doi.org/10.1016/j.suronc.2020.05.008
  27. Gastric cancer prevention strategies: A global perspective vol.35, pp.9, 2019, https://doi.org/10.1111/jgh.15037
  28. Advantages of ypTNM Staging in Post-surgical Prognosis for Initially Unresectable or Stage IV Gastric Cancers vol.20, pp.3, 2019, https://doi.org/10.5230/jgc.2020.20.e20
  29. Proximal Anterior-Antrum Posterior (PAAP) Overlapping Anastomosis in Minimally Invasive Pylorus-Preserving Gastrectomy for Early Gastric Cancer Located in the High Body and Posterior Wall of the Stoma vol.20, pp.3, 2019, https://doi.org/10.5230/jgc.2020.20.e26
  30. Prognostic Factors in Stage IB Gastric Cancer after Surgical Resection vol.20, pp.3, 2019, https://doi.org/10.5230/jgc.2020.20.e30
  31. Laparoscopic sentinel node navigation surgery versus laparoscopic gastrectomy with lymph node dissection for early gastric cancer: short‐term outcomes of a multicentre randomized controlled tria vol.107, pp.11, 2020, https://doi.org/10.1002/bjs.11655
  32. Perioperative versus postoperative chemotherapy for gastric cancer: A propensity score matched analysis vol.16, pp.5, 2019, https://doi.org/10.1111/ajco.13401
  33. Surveillance Endoscopy Guidelines for Postgastrectomy Patients Based on Risk of Developing Remnant Gastric Cancer vol.27, pp.11, 2019, https://doi.org/10.1245/s10434-020-08517-3
  34. Prognostic Impact of Frozen Section Investigation and Extent of Proximal Safety Margin in Gastric Cancer Resection vol.272, pp.5, 2020, https://doi.org/10.1097/sla.0000000000004266
  35. Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients vol.10, pp.1, 2020, https://doi.org/10.1038/s41598-020-71340-z
  36. Delta-shaped gastroduodenostomy using a robotic stapler in reduced-port totally robotic gastrectomy: its safety and efficiency compared with conventional anastomosis techniques vol.10, 2020, https://doi.org/10.1038/s41598-020-71807-z
  37. Intracorporeal esophagojejunostomy using a linear stapler in laparoscopic total gastrectomy: comparison with circular stapling technique vol.20, pp.1, 2019, https://doi.org/10.1186/s12893-020-00746-3
  38. Clinical Outcome of Novel Reconstruction of Double Shouldering Technique after Proximal Gastrectomy vol.23, pp.4, 2020, https://doi.org/10.7602/jmis.2020.23.4.191
  39. Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells vol.18, pp.4, 2019, https://doi.org/10.5808/gi.2020.18.4.e37
  40. Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer vol.20, pp.4, 2019, https://doi.org/10.5230/jgc.2020.20.e33
  41. Endoscopic Resection of Undifferentiated-type Early Gastric Cancer vol.20, pp.4, 2020, https://doi.org/10.5230/jgc.2020.20.e37
  42. Risk Factors for the Severity of Complications in Minimally Invasive Total Gastrectomy for Gastric Cancer: a Retrospective Cohort Study vol.21, 2019, https://doi.org/10.5230/jgc.2021.21.e34
  43. Intraperitoneal Paclitaxel Combined with S-1 Plus Oxaliplatin for Advanced Gastric Cancer with Peritoneal Metastasis: a Phase I Study vol.21, 2021, https://doi.org/10.5230/jgc.2021.21.e38
  44. Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses vol.13, pp.1, 2019, https://doi.org/10.3390/cancers13010059
  45. Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational vol.20, 2021, https://doi.org/10.1177/15330338211039679
  46. Importance of Examined Lymph Node Number in Accurate Staging and Enhanced Survival in Resected Gastric Adenocarcinoma—The More, the Better? A Cohort Study of 8,696 Cases From the US and China, vol.10, 2019, https://doi.org/10.3389/fonc.2020.539030
  47. Are the elderly patient's changes in the health-related quality of life one year after gastrectomy for stomach cancer different from those in young patients? vol.100, pp.1, 2019, https://doi.org/10.4174/astr.2021.100.1.8
  48. Evaluation of Lymph Node Metastasis Among Adults With Gastric Adenocarcinoma Managed With Total Gastrectomy vol.4, pp.2, 2019, https://doi.org/10.1001/jamanetworkopen.2020.35810
  49. Prognostic Value of Postoperative Neutrophil and Albumin: Reassessment One Month After Gastric Cancer Surgery vol.11, 2019, https://doi.org/10.3389/fonc.2021.633924
  50. Is Adjuvant Chemotherapy Beneficial to All Patients With pT3N0M0 Stage Gastric Cancer? vol.11, 2021, https://doi.org/10.3389/fonc.2021.712432
  51. Impact of Neoadjuvant Therapy on Minimally Invasive Surgical Outcomes in Advanced Gastric Cancer: An International Propensity Score-Matched Study vol.28, pp.3, 2019, https://doi.org/10.1245/s10434-020-09070-9
  52. Assessment of Lymph Node Metastasis in Patients With Gastric Cancer to Identify Those Suitable for Middle Segmental Gastrectomy vol.4, pp.3, 2021, https://doi.org/10.1001/jamanetworkopen.2021.1840
  53. Is it Beneficial to Utilize an Articulating Instrument in Single-Port Laparoscopic Gastrectomy? vol.21, pp.1, 2021, https://doi.org/10.5230/jgc.2021.21.e2
  54. Intraoperative Tumor Localization of Early Gastric Cancers vol.21, pp.1, 2019, https://doi.org/10.5230/jgc.2021.21.e4
  55. Long-Term Oncological Outcomes of Reduced Three-Port Laparoscopic Gastrectomy for Early-Stage Gastric Carcinoma: a Retrospective Large-Scale Multi-Institutional Study vol.21, pp.1, 2019, https://doi.org/10.5230/jgc.2021.21.e8
  56. A Novel Approach for Gastric Cancer Staging in Elderly Patients Based on the Lymph Node Ratio vol.21, pp.1, 2019, https://doi.org/10.5230/jgc.2021.21.e9
  57. Quality of life after laparoscopic sentinel node navigation surgery in early gastric cancer: a single-center cohort study vol.24, pp.3, 2019, https://doi.org/10.1007/s10120-020-01145-6
  58. Current status of robotic gastrectomy for gastric cancer: comparison with laparoscopic gastrectomy vol.73, pp.3, 2019, https://doi.org/10.1007/s13304-020-00958-5
  59. Predictors of Remission and Relapse of Diabetes after Conventional Gastrectomy for Gastric Cancer: Nationwide Population-Based Cohort Study vol.232, pp.6, 2021, https://doi.org/10.1016/j.jamcollsurg.2021.03.019
  60. Current indications for endoscopic submucosal dissection of early gastric cancer vol.13, pp.6, 2019, https://doi.org/10.4251/wjgo.v13.i6.560
  61. Incisional hernia after minimally invasive gastrectomy in gastric cancer patients vol.24, pp.2, 2021, https://doi.org/10.7602/jmis.2021.24.2.84
  62. Influence of positive margins on tumour recurrence and overall survival after gastrectomy for gastric cancer vol.91, pp.7, 2019, https://doi.org/10.1111/ans.16937
  63. Impact of Comorbidities, Sarcopenia, and Nutritional Status on the Long-Term Outcomes after Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly Patients Aged ≥ 80 Years vol.13, pp.14, 2021, https://doi.org/10.3390/cancers13143598
  64. Sp1-Induced FNBP1 Drives Rigorous 3D Cell Motility in EMT-Type Gastric Cancer Cells vol.22, pp.13, 2019, https://doi.org/10.3390/ijms22136784
  65. Metabolic Effects of Gastrectomy and Duodenal Bypass in Early Gastric Cancer Patients with T2DM: A Prospective Single-Center Cohort Study vol.10, pp.17, 2019, https://doi.org/10.3390/jcm10174008
  66. Long-term Outcomes of Undifferentiated-Type Early Gastric Cancer with Positive Horizontal Margins after Endoscopic Resection vol.15, pp.5, 2021, https://doi.org/10.5009/gnl20291
  67. Short-term outcomes of a multicentre randomized clinical trial comparing laparoscopic pylorus-preserving gastrectomy with laparoscopic distal gastrectomy for gastric cancer (the KLASS-04 trial) vol.108, pp.9, 2021, https://doi.org/10.1093/bjs/znab295
  68. Prognostic Value of the Anatomic Region of Metastatic Lymph Nodes in the Current TNM Staging of Gastric Cancer vol.21, pp.3, 2019, https://doi.org/10.5230/jgc.2021.21.e22
  69. Clinical Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer in Patients with Comorbidities vol.21, pp.3, 2019, https://doi.org/10.5230/jgc.2021.21.e25
  70. Analysis of the Occurrence of Diseases Following Gastrectomy for Early Gastric Cancer: a Nationwide Claims Study vol.21, pp.3, 2019, https://doi.org/10.5230/jgc.2021.21.e29
  71. Hybrid Robotic and Laparoscopic Gastrectomy for Gastric Cancer: Comparison with Conventional Laparoscopic Gastrectomy vol.21, pp.3, 2019, https://doi.org/10.5230/jgc.2021.21.e30
  72. Prediction of Survival Outcomes Based on Preoperative Clinical Parameters in Gastric Cancer vol.28, pp.12, 2019, https://doi.org/10.1245/s10434-021-09754-w
  73. ASO Author Reflections: Prediction of Survival Outcomes Based on Preoperative Clinical Parameters in Gastric Cancer vol.28, pp.12, 2019, https://doi.org/10.1245/s10434-021-09785-3
  74. Surgical Merits of Open, Laparoscopic, and Robotic Gastrectomy Techniques with D2 Lymphadenectomy in Obese Patients with Gastric Cancer vol.28, pp.12, 2021, https://doi.org/10.1245/s10434-021-09952-6
  75. Determination of Additional Surgery after Non-Curative Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer: A Practically Modified Application of the eCura System vol.13, pp.22, 2019, https://doi.org/10.3390/cancers13225768
  76. Prediction of risk of osteoporosis after gastrectomy for gastric cancer vol.5, pp.6, 2019, https://doi.org/10.1093/bjsopen/zrab123
  77. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer vol.44, pp.6, 2019, https://doi.org/10.1007/s13402-021-00647-4
  78. Impact of the different biliopancreatic limb length on diabetes and incretin hormone secretion following distal gastrectomy in gastric cancer patients vol.11, pp.1, 2021, https://doi.org/10.1038/s41598-021-02001-y
  79. A radiomics-based model for predicting prognosis of locally advanced gastric cancer in the preoperative setting vol.11, pp.1, 2021, https://doi.org/10.1038/s41598-021-81408-z
  80. Compliance with D2 lymph node dissection in reduced-port totally laparoscopic distal gastrectomy in patients with gastric cancer vol.11, pp.1, 2021, https://doi.org/10.1038/s41598-021-83386-8
  81. Use of direct oral anticoagulants does not significantly increase delayed bleeding after endoscopic submucosal dissection for early gastric neoplasms vol.11, pp.1, 2019, https://doi.org/10.1038/s41598-021-88656-z
  82. Textbook outcome and survival of robotic versus laparoscopic total gastrectomy for gastric cancer: a propensity score matched cohort study vol.11, pp.1, 2019, https://doi.org/10.1038/s41598-021-95017-3
  83. Postoperative morbidity and quality of life between totally laparoscopic total gastrectomy and laparoscopy-assisted total gastrectomy: a propensity-score matched analysis vol.21, pp.1, 2019, https://doi.org/10.1186/s12885-021-08744-1
  84. A comparison of postoperative outcomes after open and laparoscopic reduction of Petersen's Hernia: a multicenter observational cohort study vol.21, pp.1, 2019, https://doi.org/10.1186/s12893-021-01200-8
  85. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience vol.19, pp.1, 2021, https://doi.org/10.1186/s12957-021-02233-2
  86. Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study vol.28, pp.13, 2021, https://doi.org/10.1245/s10434-021-10084-0
  87. Lymphovascular Invasion: Traditional but Vital and Sensible Prognostic Factor in Early Gastric Cancer vol.28, pp.13, 2021, https://doi.org/10.1245/s10434-021-10224-6
  88. Is Splenic Hilar Lymph Node Dissection Without Splenectomy Essential for Proximal Advanced Gastric Cancer? vol.28, pp.13, 2019, https://doi.org/10.1245/s10434-021-10354-x
  89. Adrenal Nodules Detected at Staging CT in Patients with Resectable Gastric Cancers Have a Low Incidence of Malignancy vol.302, pp.1, 2022, https://doi.org/10.1148/radiol.2021211210